Fluidigm's Saliva Coronavirus Test Being Run by 2 Certified Labs

After receiving an emergency use authorization from the Food and Drug Administration (FDA) last month, Fluidigm (NASDAQ: FLDM) reported that its saliva-based test for the novel coronavirus that causes COVID-19 is being run at two Clinical Laboratory Improvement Amendments (CLIA) certified labs. The tests, which go by the unweildly name, Advanta Dx SARS-CoV-2 RT-PCR Assay, are being processed by ImmunoGenomics, based in metropolitan Houston, and Vero Diagnostics, of Research Triangle Park, North Carolina.